{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:51Z","timestamp":1759017891865,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clinthera.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:36:18Z","timestamp":1617186978000},"page":"844-851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study"],"prefix":"10.1016","volume":"43","author":[{"given":"Yanghui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lishuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guizhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.03.004_bib0001","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0002","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2018.01.033","article-title":"Bivalirudin or heparin in patients undergoing invasive management of acute coronary syndromes","volume":"71","author":"Gargiulo","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0003","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0004","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0005","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0007","first-page":"1172","article-title":"[Percutaneous coronary intervention for chronic total occlusion: clinical perspectives in 2015]","volume":"11","author":"Degrauwe","year":"2015","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0008","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/CIRCULATIONAHA.104.481283","article-title":"Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I","volume":"112","author":"Stone","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0009","first-page":"679","article-title":"Bivalirudin in percutaneous coronary intervention for chronic total occlusion: a single-center pilot study","volume":"91","author":"Li","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0010","first-page":"825","article-title":"Efficacy and safety of bivalirudin during percutaneous coronary intervention in high-bleeding-risk elderly patients with chronic total occlusion: a prospective randomized controlled trial","volume":"93","author":"Wang","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1536\/ihj.17-030","article-title":"Exploration of bivalirudin use during percutaneous coronary intervention for high bleeding risk patients with chronic total occlusion","volume":"59","author":"Li","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0012","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcin.2010.09.024","article-title":"Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool","volume":"4","author":"Morino","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0013","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0014","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0015","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third Universal Definition of Myocardial Infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0016","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcin.2012.10.011","article-title":"Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies","volume":"6","author":"Patel","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0017","first-page":"261","article-title":"Developments in coronary chronic total occlusion percutaneous coronary interventions: 2014 state-of-the-art update","volume":"26","author":"Brilakis","year":"2014","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0018","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/eurheartj\/ehp110","article-title":"Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial","volume":"30","author":"Mehran","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0019","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","article-title":"A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry","volume":"291","author":"Eagle","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1536\/ihj.15-195","article-title":"Incidence, predictors and impact of severe periprocedural bleeding according to VARC-2 criteria on 1-year clinical outcomes in patients after transcatheter aortic valve implantation","volume":"57","author":"Kochman","year":"2016","journal-title":"Int Heart J"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0022","doi-asserted-by":"crossref","first-page":"i4935","DOI":"10.1136\/bmj.i4935","article-title":"Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial","volume":"354","author":"Leonardi","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0023","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2008.12.021","article-title":"Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial","volume":"53","author":"Lopes","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0024","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.03.004_bib0025","first-page":"72","article-title":"Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial","volume":"10","author":"Kereiakes","year":"2009","journal-title":"Rev Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.004_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00380-020-01692-z","article-title":"Differences in lesion characteristics and patient background associated with the medium-term clinical outcomes of bare-metal and first-, second- and third-generation drug-eluting stents","volume":"36","author":"Nakamura","year":"2021","journal-title":"Heart Vessels"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:30Z","timestamp":1758963270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0149291821001120"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}